2018
New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice
Bagdas D, Alkhlaif Y, Jackson A, Carroll FI, Ditre JW, Damaj MI. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology 2018, 138: 72-79. PMID: 29860196, PMCID: PMC6054891, DOI: 10.1016/j.neuropharm.2018.05.025.Peer-Reviewed Original ResearchConceptsEffects of vareniclineNicotine withdrawal signsNicotine rewardΑ5 nAChRWithdrawal signsHigh doseKnockout miceΒ2-nAChRsNicotine withdrawal-induced hyperalgesiaAdministration of vareniclineWithdrawal-induced hyperalgesiaΑ7 knockout miceDose-related mannerNicotinic acetylcholine receptorsΑ5 knockout micePlace preference testVarenicline doseCessation treatmentNicotine withdrawalSomatic signsVareniclineΑ7 nAChRsMouse modelCPP testNicotinic subtypes
2015
Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice
Alsharari SD, King JR, Nordman JC, Muldoon PP, Jackson A, Zhu AZ, Tyndale RF, Kabbani N, Damaj MI. Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. PLOS ONE 2015, 10: e0137070. PMID: 26355604, PMCID: PMC4565647, DOI: 10.1371/journal.pone.0137070.Peer-Reviewed Original ResearchConceptsNicotine pharmacokineticsSubunit expressionBrain regionsAcute pharmacological effectsNicotine-induced antinociceptionNicotine plasma levelsMale ICR miceStriatum of miceEffect of mentholSignificant increaseAddition of mentholAdministration of mentholWestern blot analysisChronic injectionsWithdrawal signsBrain levelsICR miceNicotine cigarettesPlasma levelsSystemic administrationNicotine clearanceNicotinic receptorsPharmacological effectsNicotinic subunitsCommon flavoringEffects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice
Jackson KJ, Jackson A, Carroll FI, Damaj MI. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology 2015, 97: 270-274. PMID: 26044637, PMCID: PMC4537361, DOI: 10.1016/j.neuropharm.2015.05.023.Peer-Reviewed Original ResearchConceptsNicotine withdrawal syndromeWithdrawal syndromeKOR antagonistsAnxiety-related behaviorNicotine withdrawalSomatic signsKappa Opioid Receptor SignalingSelective KOR antagonistAffective nicotine withdrawal signsNicotine withdrawal signsOpioid receptor signalingUseful therapeutic agentShort actingHotplate latencyWithdrawal signsPharmacodynamic profileClinical studiesMood disordersLY2456302Animal modelsPlace aversionDrug dependenceTherapeutic potentialDecreased expressionAntagonist